Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo

Executive Summary

Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark

You may also be interested in...

Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo

Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.

Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C

BI's '355 has impressive response rates in early studies, but jaundice is a concern.

Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD

Next-generation ritonavir-boosted protease inhibitor is headed into Phase IIb, and if all goes well, could be a significant player in the hepatitis C market.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts